Tweaks in quality norms will drive the pharma product exports higher: DGFT

More pharm products can be brought under mandatory quality improvement norms if needed to comply with global standards for export from India if health ministry issues an advice, top official said

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Press Trust of India New Delhi
2 min read Last Updated : May 23 2023 | 5:11 PM IST

More pharmaceutical products can be brought under mandatory quality improvement norms if needed to comply with global standards for export from India if the health ministry issues an advice in this regard, a top official said on Tuesday.

Director General Foreign Trade (DGFT) Santosh Kumar Sarangi said all pharmaceutical products must meet global standards and quality requirements.

His remarks come a day after the Directorate General of Foreign Trade in a notification said cough syrup exporters will have to undertake testing of their products at specified government laboratories from June 1 before getting permission for the outbound shipments.

The direction came in the wake of quality concerns raised globally for cough syrups exported by Indian firms.

"This is a continuous effort which has been started with cough syrup. It is our endeavour that any cough syrup exported from India must meet minimum benchmark requirement of quality standards. Therefore they will be exported after being tested in specified labs," Sarangi said at an event.

"As per CDSCO's (Central Drugs Standard Control Organisation) advice, whatever needs to be done for quality improvement in pharma will be done," he added.

Asked whether other pharmaceutical products will be brought under similar quality improvement norms for export from India, he said, as per CDSCO and the health ministry's advice, wherever there is a need of more stringent global benchmarking for pharma products, it will be done.

The export of cough syrup shall be permitted to be exported subject to export samples being tested and production of certificate of analysis issued by any of the laboratories with effect from June 1, 2023, the DGFT said in a notification on Monday.

The specified central government labs include Indian Pharmacopoeia Commission, regional drug testing lab (RDTL - Chandigarh), central drugs lab (CDL - Kolkata), central drug testing lab (CDTL - Chennai Hyderabad, Mumbai), RDTL (Guwahati), and NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited drug testing labs of state governments.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Pharma sectorDGFT

First Published: May 23 2023 | 5:11 PM IST

Next Story